National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 51293-51294 [E9-23978]
Download as PDF
<![CDATA[
jlentini on DSKJ8SOYB1PROD with NOTICES
Federal Register / Vol. 74, No. 192 / Tuesday, October 6, 2009 / Notices
line/phone line to learn about possible
modifications before coming to the
meeting.
Agenda: On December 8, 2009, the
committee will discuss safety
considerations related to FDA-approved
gadolinium-based contrast agents used
with magnetic resonance imaging (MRI)
scans. An MRI is a medical imaging
technique that does not require x-rays.
These scans outline the internal body
structures such as organs and other soft
tissues. Contrast agents are substances
injected into the body before MRI scans,
helping doctors to better see and
interpret MRI findings. FDA approved
gadolinium-based contrast agents
include: gadobenate dimeglumine
(MULTIHANCE), gadodiamide
(OMNISCAN), gadopentetate
dimeglumine (MAGNEVIST),
gadoteridol (PROHANCE),
gadoversetamide (OPTIMARK),
gadoxetate disodium (EOVIST), and
gadofosveset (ABLAVAR, previously
known as VASOVIST).
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before November 23, 2009.
Oral presentations from the public will
be scheduled between approximately 1
p.m. to 2 p.m. Those desiring to make
formal oral presentations should notify
the contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before November 13, 2009. Time
allotted for each presentation may be
limited. If the number of registrants
requesting to speak is greater than can
be reasonably accommodated during the
scheduled open public hearing session,
FDA may conduct a lottery to determine
the speakers for the scheduled open
public hearing session. The contact
person will notify interested persons
VerDate Nov<24>2008
16:15 Oct 05, 2009
Jkt 220001
regarding their request to speak by
November 16, 2009.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Elaine
Ferguson at least 7 days in advance of
the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: October 1, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9–24014 Filed 10–5–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; International Collaborations
in Infectious Disease Research (ICIDR).
Date: November 2, 2009.
Time: 10:30 a.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20817
(Telephone Conference Call).
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
51293
Contact Person: Gary S. Madonna, PhD,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institutes of Health/NIAID, 6700B
Rockledge Drive, Bethesda, MD 20892, (301)
496–3528, gm12w@nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; International Collaborations
in Infectious Disease Research (ICIDR).
Date: November 4, 2009.
Time: 10:30 a.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20817
(Telephone Conference Call).
Contact Person: Gary S. Madonna, PhD,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institutes of Health/NIAID, 6700B
Rockledge Drive, Bethesda, MD 20892, (301)
496–3528, gm12w@nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; International Collaborations
in Infectious Disease Research (ICIDR).
Date: November 6, 2009.
Time: 10:30 a.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20817
(Telephone Conference Call).
Contact Person: Gary S. Madonna, PhD,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institutes of Health/NIAID, 6700B
Rockledge Drive, Bethesda, MD 20892, (301)
496–3528, gm12w@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: September 29, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–23979 Filed 10–5–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
E:\FR\FM\06OCN1.SGM
06OCN1
51294
Federal Register / Vol. 74, No. 192 / Tuesday, October 6, 2009 / Notices
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; HIV Research Support.
Date: October 28, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate contract
proposals.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Rockville, MD 20852.
Contact Person: Eric Lorenzo, PhD,
Scientific Review Officer, Scientific Review
Program, DEA/NIAID/NIH/DHHS, Room
2217, 6700B Rockledge Drive, MSC–7616,
Bethesda, MD 20892–7616. 301–496–2550.
lorenzoe@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: September 29, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–23978 Filed 10–5–09; 8:45 am]
BILLING CODE 4140–01–P
Review Branch, National Institute on Aging,
7201 Wisconsin Avenue, Suite 2C212,
Bethesda, MD 20892. 301–496–9666.
markowsa@nia.nih.gov.
Name of Committee: National Institute on
Aging Special Emphasis Panel. Cardiac
Progenitor Cells and Aging.
Date: November 10, 2009.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
2C212, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Elaine Lewis, PhD,
Scientific Review Officer, Scientific Review
Branch, National Institute on Aging, Gateway
Building, Suite 2C212, MSC–9205, 7201
Wisconsin Avenue, Bethesda, MD 20892.
301–402–7707. elainelewis@nia.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Mental Health, NIH, Neuroscience Center,
6001 Executive Blvd, Room 6149, MSC 9608,
Bethesda, MD 20892–9608. 301–443–4525.
steinerr@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.242, Mental Health Research
Grants; 93.281, Scientist Development
Award, Scientist Development Award for
Clinicians, and Research Scientist Award;
93.282, Mental Health National Research
Service Awards for Research Training,
National Institutes of Health, HHS)
Dated: September 29, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–23977 Filed 10–5–09; 8:45 am]
National Institutes of Health
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meeting
National Institute on Aging; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
jlentini on DSKJ8SOYB1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel. Brain
Dopamine.
Date: October 29, 2009.
Time: 1 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
2C212, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Alicja L Markowska, PhD,
DSC, Scientific Review Officer, Scientific
VerDate Nov<24>2008
16:15 Oct 05, 2009
Jkt 220001
Name of Committee: National Institute of
Mental Health Special Emphasis Panel,
Building Translational Research in
Integrative Behavioral Science.
Date: November 4, 2009.
Time: 3 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call.)
Contact Person: Rebecca C Steiner, PhD,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
Dated: September 29, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–23976 Filed 10–5–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute of Mental Health;
Notice of Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of an Interagency Autism
Coordinating Committee (IACC)
meeting.
The purpose of the IACC meeting is
to discuss recommendations for the
annual update of the IACC Strategic
Plan for Autism Spectrum Disorders
Research. The meeting will be open to
the public and will be accessible by
webcast and conference call.
Name of Committee: Interagency Autism
Coordinating Committee (IACC).
Type of meeting: Open.
Date: October 23, 2009.
Time: 9 a.m. to 5 p.m.* Eastern Time—
*Approximate end time.
Agenda: A presentation by a panel of
parents of children with autism; a
presentation on Applied Behavioral Analysis
by Dr. Tony Charman; and discussion of
recommendations for updating the IACC
Strategic Plan for Autism Spectrum Disorders
Research.
Place: The National Institutes of Health,
Main Campus, William H. Natcher
Conference Center, 45 Center Drive,
Conference Rooms E1/E2, Bethesda, MD
20892.
Webcast Live: https://videocast.nih.gov/.
Conference Call Access: Dial: 888–455–
2920; Access code: 3132846.
Cost: The meeting is free and open to the
public.
Registration: https://
www.acclaroresearch.com/oarc/10–23–
09_IACC/. Pre-registration is recommended
to expedite check-in. Seating in the meeting
room is limited to room capacity and on a
first come, first served basis.
Access: Metro accessible—Red Line—
Medical Center Metro Station.
E:\FR\FM\06OCN1.SGM
06OCN1
]]>Agencies
[Federal Register Volume 74, Number 192 (Tuesday, October 6, 2009)]
[Notices]
[Pages 51293-51294]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-23978]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The contract proposals and the discussions could
disclose confidential trade secrets or commercial
[[Page 51294]]
property such as patentable material, and personal information
concerning individuals associated with the contract proposals, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; HIV Research Support.
Date: October 28, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate contract proposals.
Place: Hilton Washington/Rockville, 1750 Rockville Pike,
Rockville, MD 20852.
Contact Person: Eric Lorenzo, PhD, Scientific Review Officer,
Scientific Review Program, DEA/NIAID/NIH/DHHS, Room 2217, 6700B
Rockledge Drive, MSC-7616, Bethesda, MD 20892-7616. 301-496-2550.
lorenzoe@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: September 29, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-23978 Filed 10-5-09; 8:45 am]
BILLING CODE 4140-01-P
